REQUEST A QUOTE
REQUEST A QUOTE

Google Search

Search

Already a Member ?

Register Now!

Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Drug Intermediates, Speciality Chemicals, Raw Materials, Fine and Specialty Chemicals Intermediates, Pharmaceutical Bulk Drugs

Indian drugs and pharmaceutical industry has advanced perceptibly and is getting ready  for the new patent regime and  to withstand global competition, which is expected to be unleashed by new winds of liberalisation - a new era of liberalisation - much different from what was ushered in since the conclusion of the Uruguay Round and the establishment of the World Trade Organisation.

The industry has been expanding at annual rates ranging between 8 to 10% (against global growth rate of 6%).  According to a study  by McKinsey, Vision 2010, the domestic pharmaceutical industry could attain a size of  $25 billion (Rs 1200 billion) by 2010 by focusing on two areas: first, innovation-led research, development and new drug discoveries; and second, information technology-led remote sales and marketing.  The market for bulk drugs and formulations had increased from about Rs 103  billion in 1990-91 to an estimated Rs 435  billion at the end of 2003-04.  The prices of Indian essential drugs are among the lowest in the world. Apart from strides made by the industry in the last half-a-century, lower production cost due to reverse engineering and low R&D outlays has been a major factor in keeping the prices under check.

The global pharmaceutical industry is estimated at $ 300 billion, not all representing cross-border trade.  India's measly share of $ 1.5 billion in global trade represents an untapped potential. Under the regime of economic liberalisation underway since early 1990s, the drugs and pharmaceutical sector witnessed initiatives at fresh investment in the sector. Nearly 1735 investment proposals of the order of around Rs 166  billion were initiated. The foreign collaboration proposals approved numbered around 425 with a foreign direct investment  (FDI) component of over Rs 25 billion. The pharmaceuticals have figured high on the export front. In 2001-02,  the sector was  estimated to have registered a growth of 17.6% at around Rs 20.3 billion.

In the wake of economic liberalisation, many a  overseas players  returned or contemplated returning to India. These include Ivox Corp (USA),  Taro Pharmaceuticals (Israel) and Merck (USA). These are out either to set shop or looking for acquisitions in India. Hexal AG of Germany has established a liaison office in India. MILLIONCs like Rocha, Bayer, Aventis and Chiron are making India a regional hub for bulk drugs. 

The Export Import Bank of India (Exim Bank) had  doubled its corpus for the pharmaceutical industry to Rs 2 billion as a result of increased activity in the industry, especially in the external sector. The fund is used for the development and commercialisation of the new products and applications, significant improvement in the existing design of  products, setting up and expansion of pilot plants, research studies for obtaining regulatory approvals, cost of filing and managing international patent and R&D Centres.

It needs, however, to be recognised that the presence  of small scale manufacturers has resulted, on the one hand,  in a highly fragmented industry, and on the other, it has made it possible to supply a near 100,000 drugs including vitamins, antibiotics, antibacterials, cardio-vascular and other essential drugs. These account for nearly 37% of the market.  While each of about 80% of the manufacturers has annual sales below a billion rupees, top ten companies are known to control over 30% of the market. At present there are more than 20,000 players in the country.

The major players are: Alembic Chem, Aurobindo Pharma, Cipla, Dr. Reddy's, FDC, IPCA Labs, Jagsonpal Pharma, J.B. Chemicals, Kopran, Lupin Labs, Lyka Labs, Morepan Labs, Nicholas Piramal, Ranbaxy Labs, Sun Pharma, Themis Medicare, GlaxoSmithkline, Astrazeneca, Aventis, E-Merck, Torrent Pharma, TTK Healthcare, Unichem Labs,  Wockhardt  and  Zandu Pharma.  Until recently, only a few of the Indian companies had gone into any serious R&D activity. Much of the effort was directed to affordable analogue research. The R&D level in the country is low with even well-placed pharma companies spending less than 2% of turnover on R&D. MILLIONCs are known to contribute as much as 10% or more of their turnover to R&D.  While India is very strong in process chemistry, biology and applied bio-chemistry, initiatives at all levels - government, academia, private sector - involving heavy financial outlays, are called for.

Ayurveda continues to remain a preferred system of medicine for a vast segment of population in the country. The country has over 400,000 registered practitioners of the Indian system of medicine. Around 170 institutes properly affiliated to various universities impart under- or post-graduate courses each year. These institutes churn out some 5,500 fresh practitioners. The practitioners are supported by 12,000 dispensaries and 2,100 beds available for ayurveda treatment countrywide. The emerging biotechnology sector has already taken by storm and is offering sops to states to make these as the thriving ground for the highly potential segment in medicare.

How to Prepare Project Report on Pharmaceutical Processing Industry?

Drug manufacturing companies work under strict laws and regulations. Their processes need to comply with relevant drugs act in their respective countries.

Therefore, if you are planning to invest in pharmaceutical processing, a good project report will be necessary. Besides the prominent aspects of a project report, you should pay close attention to the following issues in a pharmaceutical processing report.

1. Marketing

This industry is very competitive. I need not stress the value of detailed market analysis. You need to understand the status of market competition and the demand for pharmaceutical products. A proper market analysis will additionally help you prepare an excellent pharmaceutical business plan. Given your market analysis report, you will develop a marketing plan.

2. Government approval

In almost all countries, there are laws and regulations for the manufacture, distribution, and administration of drugs. Consider giving a status report on these requirements when making the final project status report.

3. Manufacturing Process

It would help if you had a picture of the process you will employ in making your drugs. Outline the quality checks and balances in the process. State the required pharmaceutical intermediates and their corresponding active pharmaceutical ingredients.

4. Machines and Equipment

You need to identify the equipment you will need, such as homogenizers, spectrophotometer, tabulating machines, etc. to ensure the machines meet quality specifications. You may also need to put down a plan to train workers on their operations.

How Does the Drug Manufacturing Process Work?

If you are an aspiring drug manufacturer, you should know how the bulk drug manufacturing process works. This is a complicated process and requires professional skills in molecular biology, medical microbiology, and pharmacy.

The process involves four steps, namely:

  • Milling
  • Granulation
  • Coating
  • Tabulation

Milling is important because it makes the drug powder uniform. It ensures uniform distribution of the active pharmaceutical ingredients. Additionally, milling makes it easier to formulate the drug into a syrup or emulsion.

After milling, you can use wet or dry granulation to form granules. You then coat them and compress the drugs using a tabulating machine. Alternatively, you can fill the granules into capsules.

For any chemical industry business ideas, prioritize the security of your staff. Ensure workers have sufficient PPEs. Have plans to protect them from chemical poisoning. Install eyewashes and emergency showers in both production units and laboratories.

Pre-Feasibility Report on Bulk Drug Manufacturing Process

Before you set up a feasibility report or start making a business plan, you first need to do a pre-feasibility study. It is the conclusions of this study that will make you decide whether to proceed to the project feasibility report or not.

Implementing a pharmacy business plan is an expensive affair. Please do not put any investment into a business plan of this magnitude without looking at its feasibility study report.

Considering the variety of pharmaceutical products, a feasibility plan will help you decide on the most relevant product for your target market. The results of pre-feasibility and feasibility studies will inform your marketing strategy plan. At the pre-feasibility stage, you get to review the technical skills required for the bulk drug manufacturing process. You also assess the knowledge level and determine whether you have the knowledge and skills.

Lastly, this report looks at the financial demands of a chemical project report on bulk drug processing. From here, you will decide on the feasibility of the project.

How to Grow Pharmaceutical Intermediates Market?

The pharmaceutical industry relies on pharmaceutical intermediates. We use these chemicals to produce active pharmaceutical ingredients (API). 

To grow the pharmaceutical intermediates market, therefore, we should focus on the drug manufacturing industry. Here are some tips on how we can grow this industry.

1. Investment in Research and Development

We should encourage governments and established drug manufacturers to invest in research and development of new medicines. New drug development will increase the need for pharmaceutical intermediates. Consequently, this will cause the growth of the industry.

2. Boost Generic Drug Manufacturing

Feasibility study reports for project ideas in pharmaceuticals show a growing demand for generics. This demand is particularly high in developing countries. More investment in generic drugs will result in increased demand for pharmaceutical intermediates.

3. Collaborations

It is quite expensive to run a pharmaceutical intermediate processing company. If you look at a project summary example for the local industry and you will notice the huge investment. One way of cushioning the industry is to encourage collaborations, mergers, and acquisitions. Working together gives small-scale companies a competitive advantage. It lowers their operation costs and improves revenue.

How to Set Up a Chemical Industry Business Plan?

Writing a chemical industry business plan begins with a pre-feasibility study. Here, you look at the various business ideas in chemical manufacturing. You then evaluate each of these ideas based on:

1. Skills and Knowledge

If you are interested in the chemical manufacturing industry, I assume that you have some skills or knowledge in this sector. If so, look at the skills required for each idea you have. Which of these ideas marches your skills and knowledge?

2. Financial Resources

Different chemical processes have different cost implications. Try to review each idea against the expected financial input. You can examine some business plan examples on the internet to get a hint on required inputs. Once you have a convincing pre-feasibility report, you can proceed to make a feasibility report meaning the idea is profitable and viable.

The next step in setting up a chemical industry business plan is to prepare a small business marketing plan. The results of your feasibility report will help do this.

Chemical manufacturing is not only expensive, but it is also strictly regulated by law. It would be best if you had an innovative marketing strategy to break even. It would be best if you did an accurate market analysis.

A project report on the pharmaceutical industry helps you assess the dynamics of the industry. You will want to know who the major chemical manufacturers are. You will also assess the availability of raw materials and machinery for your pharmaceutical industry.

In your project report, you will also address the technical aspects of the pharmaceutical manufacturing process. You need to draw a flow diagram for the process. Lastly, sit down and draw a business plan for your chemical industry business. You will need the information from all the above processes. Additionally, a business plan will consider the financial implications of your pharmaceutical industry project report.


We can provide you detailed project reports on the following topics. Please select the projects of your interests.

Each detailed project reports cover all the aspects of business, from analysing the market, confirming availability of various necessities such as plant & machinery, raw materials to forecasting the financial requirements. The scope of the report includes assessing market potential, negotiating with collaborators, investment decision making, corporate diversification planning etc. in a very planned manner by formulating detailed manufacturing techniques and forecasting financial aspects by estimating the cost of raw material, formulating the cash flow statement, projecting the balance sheet etc.

We also offer self-contained Pre-Investment and Pre-Feasibility Studies, Market Surveys and Studies, Preparation of Techno-Economic Feasibility Reports, Identification and Selection of Plant and Machinery, Manufacturing Process and or Equipment required, General Guidance, Technical and Commercial Counseling for setting up new industrial projects on the following topics.

Many of the engineers, project consultant & industrial consultancy firms in India and worldwide use our project reports as one of the input in doing their analysis.

We can modify the project capacity and project cost as per your requirement.
We can also prepare project report on any subject as per your requirement.

Page 20 of 26 | Total 259 projects in this category
« Previous   Page 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 .... 20 25 26   Next »

Add multiple items to inquiry
Select the items and then press Add to inquiry button

Select all | Clear all Sort by

IV Fluids in Plastic Bottles (IV Solution Automatic System)

Intravenous fluids are fluids which are intended to be administered to a patient intravenously, directly through the circulatory system. These fluids must be sterile to protect patients from injury, and there are a number of different types available for use.The basic function of IV fluids is to replenish the body fluids.Intravenous fluids can also be used as a route of medication administration. The market for Intravenous (IV) Solution is expected to reach USD 11,511.2 million by 2022 and is expected to grow at a CAGR of 7.69% during the forecast period 2016-2022. The factors which drive the growth of the market are the rising prevalence of chronic diseases, rising acceptance of vitamin C intravenous treatment therapy to treat colorectal cancer.Entrepreneurs who invest in this project will be successful. Few Indian major players are as under • Abaris Healthcare Pvt. Ltd. • AhlconParenterals (India) Ltd. • AxaParenterals Ltd. • Infutec Healthcare Ltd. • Kokad Pharmaceutical Laboratories Ltd. • Parenteral Surgicals Ltd.
Plant capacity: IV Fluids (500 ml Bottle): 40000 Pcs./dayPlant & machinery: Rs. 2658 lakhs
Working capital: -T.C.I: Cost of Project: Rs10817 lakhs
Return: 17.00%Break even: 25.00%
Add to Inquiry Add to Inquiry Basket

Microcrystalline Cellulose (Pharmaceutical Grade)

Microcrystalline cellulose (MCC) is a term for refined wood pulp and is used as a texturizer, an anti-caking agent, a fat substitute, an emulsifier, an extender, and a bulking agent in food production. The most common form is used in vitamin supplements or tablets. It is also used in plaque assays for counting viruses, as an alternative to carboxymethyl cellulose. Microcrystalline Cellulose Market size is projected to grow from USD 885.1 million in 2018 to USD 1,241.4 million by 2023, at a CAGR of 7.0% between 2018 and 2023 and is forecast to exceed USD 1.2 billion by 2024.Which facilitates the development of new technologies and ensure a high quality product.
Plant capacity: Microcrystalline Celluose (Pharmaceutical Grade): 5 MT/dayPlant & machinery: Rs 74 lakhs
Working capital: -T.C.I: Cost of Project: Rs 277 lakhs
Return: 29.00%Break even: 78.00%
Add to Inquiry Add to Inquiry Basket

X-ray Films

X-ray film displays the radiographic image and consists of emulsion (single or double) of silver halide (silver bromide (AgBr) is most common) which when exposed to light, produces a silver ion (Ag+) and an electron. The electrons get attached to the sensitivity specks and attract the silver ion. X-ray films for general radiography consist of an emulsion-gelatin containing radiation sensitive silver halide crystals, such as silver bromide or silver chloride, and a flexible, transparent, blue-tinted base. The emulsion is different from those used in other types of photography films to account for the distinct characteristics of gamma rays and x-rays, but X-ray films are sensitive to light. The global X-ray film market is expected to register a CAGR of 5% over the forecast period of 2018–2023. In the medical industry, the usage of X-ray films in dental inspection, mammograms, and orthopedic inspection hold the major share in the market. The industrial sector has a long established usage of X-ray films and is widely used in NDT methods for volumetric examination radiography. The presence of X-ray machines in hospitals enables physicians in detection of somatic issues, as well as trauma. X-ray is very useful for detection and treatment of neurological problems, cancer, cardiac diseases and bone related problems. The existing pervasiveness of these issues will increase demand for the product over the forecast period.
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Sulfamethoxazole

Sulfamethoxazole is an antibiotic. It is used for bacterial infections such as urinary tract infections, bronchitis, and prostatitis and is effective against both gram negative and positive bacteria such as Listeria monocytogenes and E. coli. Sulfamethoxazole is a bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. Sulfamethoxazole and trimethoprim combination is used to treat infections such as urinary tract infections, middle ear infections (otitis media), bronchitis, traveler's diarrhea, and shigellosis (bacillary dysentery). This medicine is also used to prevent or treat Pneumocystis jiroveci pneumonia or Pneumocystis carinii pneumonia (PCP), a very serious kind of pneumonia. Sulfamethoxazole is a sulfonamide bacteriostatic antibiotic that is most commonly used in combination with trimethoprim as the drug Bactrim. Sulfamethoxazole competitively inhibits dihydropteroate synthase preventing the formation of dihydropteroic acid, a precursor of folic acid which is required for bacterial growth.
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Ringer's Lactate Solution

Ringer's lactate solution (RL), also known as sodium lactate solution and Hartmann's solution, is a mixture of sodium chloride, sodium lactate, potassium chloride, and calcium chloride in water. It is used for replacing fluids and electrolytes in those who have low blood volume or low blood pressure. It may also be used to treat metabolic acidosis in cases other than those caused by lactic acidosis and to wash the eye following a chemical burn. It is given by injection into a vein or applied to the affected area. Ringer’s lactate solution, or lactated Ringer’s solution, is a type of isotonic, crystalloid fluid further classified as a balanced or buffered solution used for fluid replacement. The contents of Ringer’s lactate include sodium, chloride, potassium, calcium, and lactate in the form of sodium lactate, mixed into a solution with an osmolarity of 273 mOsm/L and pH of about 6.5. In comparison, normal saline (NS) has an osmolarity of about 286 mOsm/L. Ringer Lactate R Solution is especially useful for the control of excessive vomiting, diarrhoea, dehydration or in infectious diseases such as cholera. It is administered either through an intravenous fluid injection or through a process known as electrolyte therapy.
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Empty Hard Gelatin Capsules

Hard gelatin capsules are made of two shells: the capsule body and a shorter cap. They are clear, colorless, and essentially tasteless. Two-piece capsules have been used for almost a century in the pharmaceutical field and the gelatin has been adopted as the main material of these capsules due to its excellent characteristic as a gelatinizer. The global empty hard gelatin capsules market was valued at $1,841.5 million in 2017 and is expected to reach $3,707.5 million by 2025, registering a CAGR of 9.1% from 2018 to 2025. Capsules are relatively stable shells that contain or encapsulate medicines, which are administered in a variety of dosage forms. As a whole there is a good scope for new entrepreneur to invest in this business. Few Indian major players are as under • A B L Biotechnologies Ltd. • A C G Arts & Properties Pvt. Ltd. • Akums Drugs & Pharmaceuticals Ltd. • Capsugel Healthcare Ltd. • Chemcaps Ltd. • Dinesh Remedies Ltd.
Plant capacity: 2500 Th.Nos./ dayPlant & machinery: Rs 1565 lakhs
Working capital: -T.C.I: Cost of Project: Rs 2149 lakhs
Return: 28.00%Break even: 49.00%
Add to Inquiry Add to Inquiry Basket

Saline and Dextrose Fluid (IV)

Saline is a general phrase referring to a sterile solution of sodium chloride in water, but is only sterile when it is to be placed parenterally; otherwise, a saline solution is a salt water solution. The sterile solution is typically used for intravenous infusion, rinsing contact lenses, nasal irrigation, and often used to clean a new piercing. Dextrose Solution (5%) is an isotonic solution and supplies calories to human body instantaneously without disturbing the electrotype balance. The global Intravenous (IV) solutions market was valued at USD 6.9 billion in 2015 and is projected to grow at a CAGR of 7.8% over the forecast period. And is expected to reach a value of USD 13.79 billion by 2024. As a whole there is a good scope for new entrepreneur to invest in this business. Few Indian major players are as under • Amanta Healthcare Ltd. • Axa Parenterals Ltd. • Infutec Healthcare Ltd. • Kokad Pharmaceutical Laboratories Ltd. • Parenteral Drugs (India) Ltd. • Parenteral Surgicals Ltd.
Plant capacity: Dextrose IV Fluid (100 ml Size) : 7800 Bottles/Day Dextrose-Sodium Chloride IV Fluid (250 ml Size): 7200 Bottles/Day Sodium Chloride IV Fluid (500 ml Size): 6200 Bottles/Day Ciprofloxacin (100 gm Size) Bye Product: 250 Bottles/Day FluconazolPlant & machinery: Rs 2281 lakhs
Working capital: -T.C.I: Cost of Project: Rs 3200 lakhs
Return: 28.00%Break even: 34.00%
Add to Inquiry Add to Inquiry Basket

Empty Hard Gelatin Capsules Manufacturing Industry

Empty Hard Gelatin Capsules Manufacturing Industry. Production of Empty Gel Capsules. Pharmaceutical Capsule Manufacture Gelatin is considered to be animal proteins that are utilized to prepare capsules, which gives calculated quantities of products. Empty hard gelatin capsules are made from gelatin (Gelatin is a translucent, colorless, brittle (when dry), flavorless solid substance, derived from the collagen- an animal protein). Empty Hard Gelatin Capsules contain 12 – 16% moisture. But the moisture content can vary up on the storage conditions. Empty gelatin capsules are available in various colors and color combinations including transparent and metallic capsules. Widely demanded in food, cosmetics and pharmaceutical industry, Empty Hard Gelatin Capsules are used for strengthening bones, improving air quality and various other uses. It is used for filling the solid substance. Features: • Hermetically sealed and airtight • Increase the bio-availability of poorly soluble nutrients • Longer shelf life • Easily digested and dissolved within minutes • Safe to consume • Fast relief Advantage of Gelatin Capsules There are following importance of gelatin capsules: ? It is taste less, odorless and easy to administration. ? They are attractive to appearance. ? Easy to handle and carry. ? Drug having an unpleasant odor and placed in the closed shell. ? Rapid drug release possible. ? Flexibility of formulation • No need to form a compact that must stand up to handling. • Unique mixed fills possible. • Role in drug development. • Role in clinical tests. ? Sealed HGCs are good barriers to atmospheric oxygen. Market Outlook Indian EHGC market is estimated at approx 64 billion capsules in absolute production terms. The global empty capsules market was valued at $1,841.5 million in 2017 and is expected to reach $3,707.5 million by 2025, registering a CAGR of 9.1% from 2018 to 2025. Capsules are relatively stable shells that contain or encapsulate medicines, which are administered in a variety of dosage forms. Empty capsules are of two types in the market namely, gelatin capsules and non-gelatin capsules. Of these, the vegetable/non-gelatin capsules are expected to witness considerable demand in the coming years. This is attributed to the preference for the same among the consumers due to its natural or non-animal origin. The growth of the nutraceuticals industry has provided a shot in the arm to the global empty capsules market. Nutraceuticals have become popular across a range of demographics and regions due to their convenience in complementing a regular diet and help the individual maintain optimum health. The increasing adoption of unhealthy lifestyles by urban consumers across the world, particularly in developed regions, has led to growing demand for nutraceuticals, which is likely to remain a key driver for the global empty capsules market in the coming years. Apart from nutraceuticals, the branching out of the pharmaceuticals industry into the cosmeceuticals sector also has significant potential for the empty capsules market. The demand for capsules is growing on account of the mounting consumption of medicines worldwide. This trend augurs well for the global empty capsules market, where growth has thus far been driven by the demand for both nongelatin and hard gelatin capsules. The changing demographics of the world have necessitated the greater production of medicines to treat various kinds of diseases. Capsules, being among the most versatile forms of administering drug doses, are thus expected to be consumed in larger volumes over the next few years. The consumption demand for empty capsules is shaped by factors like health conditions of the aging population, clinical trial testing of formulations, changing consumer lifestyles, and edible beauty products with specific application in pharma, nutraceutical, and cosmetic industries. The key factors that boost the growth of the global empty capsules market include growth in popularity of capsules over other drug delivery forms and increase in strategic collaborations between empty capsule suppliers and gelatin manufacturers. In addition, rapid advancements in capsule delivery technologies are set to supplement the market growth. However, ethical concerns, price fluctuations regarding gelatin material, and stringent regulations in the pharmaceutical industry are expected to hamper the market growth. Nevertheless, soaring investments by pharmaceutical manufacturers in untapped economies offer profitable opportunities for the expansion of the market. The demand for empty capsules is expected to rise substantially in the years ahead thanks largely to the overall growth and expansion of the global pharmaceuticals industry. Moreover, the greater demand for nutraceuticals will also provide the global capsules market an opportunity to expand as several food supplements and functional foods are encapsulated to make them convenient for on-the-go consumption. The empty capsules market is dominated by top three players, namely, Capsugel (US), ACG Worldwide (India), and Qualicaps (Japan). Some of the other key players in this market are Suheung Co. Ltd. (Korea), CapsCanada Corporation (Canada), Qingdao Yiqing Medicinal Capsules Co., Ltd. (China), Shanxi Guangsheng Medicinal Capsules Co., Ltd (China), Healthcaps India Ltd. (India), Snail Pharma Industry Co. Ltd. (China), Roxlor (US), Sunil Healthcare Ltd. (India), Medi-Caps Ltd. (India), Nectar Lifesciences Ltd. (India), Natural Capsules Ltd. (India), and Bright Pharma Caps Inc. (US). Tags #Hard_Gelatin_Capsules, #Empty_Hard_Gelatin_Capsules, #Gelatin_Capsules, Manufacturing of Empty Hard Gelatin Capsules, #Empty_Hard_Gelatin_Capsules_Manufacture, Hard Gelatin Capsule Manufacturing Process Pdf, Preparation of Empty Gelatin Capsule, Empty Capsules, #Gelatin_Capsule_Manufacture, Capsule Manufacture, Capsule Manufacturing, Empty Gelatin Capsules, #Production_of_Empty_Hard_Gelatin, Manufacture of Hard Gelatin Capsules, Pharmaceutical Capsule Manufacture, Empty Capsules, Empty Gel Capsules, Gelatin Capsule Manufacturing Business, Gelatin Capsule Manufacturing, #How_to_Start_Empty_Gelatin_Capsule_Manufacturing_Business, Hard Gelatin Capsule Manufacturing Plant, Capsule Manufacture, Empty Gelatin Capsule Manufacturing Process, Capsule Production, Hard Gelatin Capsule Manufacturing Process, #Hard_Gelatin_Capsule_Manufacturing_Process_Pdf, Empty Hard Gelatin Capsules Production, Empty Capsule Production, Empty Capsule Making Business, How Empty Gelatin Capsules are Produced, Capsule Manufacturing Process Flow Chart, Manufacturing of Empty Gelatin Capsules, Project Report on Gelatin Capsule Manufacturing Industry, #Detailed_Project_Report_on_Empty_Hard_Gelatin_Capsules_Production, Project Report on Empty Hard Gelatin Capsules Production, Pre-Investment Feasibility Study on Empty Gelatin Capsule Manufacturing Business, Techno-Economic feasibility study on Empty Hard Gelatin Capsules Production, #Feasibility_report_on_Hard_Gelatin_Capsule_Manufacturing_Business, Free Project Profile on Hard Gelatin Capsule Manufacturing Industry, Project profile on Gelatin Capsule Manufacturing, Download free project profile on Empty Hard Gelatin Capsules Production
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

IV Fluids (BFS Technology)

In nursing homes and hospital where patients are suffering from acute dehydration or considerable debilitating conditions, the intra venous fluids are used as IV drips. The basic function of IV fluids is to replenish the body fluids. Although there are a number of IV fluids but generally three types of IV fluids are used in hospitals as IV drips. Intravenous fluids are fluids which are intended to be administered to a patient intravenously, directly through the circulatory system. These fluids must be sterile to protect patients from injury, and there are a number of different types available for use. Many companies manufacture packaged intravenous fluids, as well as products which can be mixed with sterile water to prepare a solution for intravenous administration. Fluids are given when someone's body fluid volume falls. There are a number of things which can cause a drop in fluid volume. Vomiting and diarrhea are a classic example, which is why people are encouraged to drink fluids when they are sick, to keep their fluid volume stable. The market for Intravenous (IV) Solution is expected to reach USD 11,511.2 million by 2022 and is expected to grow at a CAGR of 7.69% during the forecast period 2016-2022. Intravenous (IV) solutions are fluids which are intended to be administered to a patient directly into the venous circulation. These fluids are sterile fluids which protects patients at the time of serious dehydration. There are various type of IV solutions available for use in the market. Many companies manufactures packaged intravenous fluids or products or compounds which can be mixed with sterile water to prepare a solution for intravenous administration. The global Intravenous (IV) solutions market was valued at USD 6.9 billion in 2015 and is projected to grow at a CAGR of 7.8% over the forecast period. The emergence of this market is attributed to the fast growing geriatric population and prevalence of malnutrition in the elderly and pediatric population. ? Few Indian major players are as under: • Abaris Healthcare Pvt. Ltd. • Ahlcon Parenterals (India) Ltd. • Axa Parenterals Ltd. • Infutec Healthcare Ltd. • Kokad Pharmaceutical Laboratories Ltd. • Parenteral Surgicals Ltd. • Pharmazell (India) Pvt. Ltd.
Plant capacity: IV Fluids (500 ml Size Pack):55,000 Packs per day IV Fluids (200 ml Size Pack):65,000 Packs per dayPlant & machinery: 2543 Lakh
Working capital: -T.C.I: Cost of Project:3277 Lakh
Return: 28.00%Break even: 42.00%
Add to Inquiry Add to Inquiry Basket

Investment Opportunities in API Bulk Drugs & Intermediates Manufacturing Unit

Investment Opportunities in API Bulk Drugs & Intermediates Manufacturing Unit. Govt Announces Rs. 13,760-Cr Package to Boost API & Medical Device Production in India. Active Pharmaceutical Ingredient (API) API (Active Pharmaceutical Ingredient) means the active ingredient which is contained in medicine. For example, an active ingredient to relieve pain is included in a painkiller. This is called API. A small amount of the active ingredient has an effect, so only a tiny part of the active ingredient is contained in medicine. Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. Related Projects: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Related Books: - Pharmaceutical, Drugs, Proteins Technology Handbooks Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Related videos: - Manufacturing Business Ideas in Pharmaceutical Industry Manufacturing of Pharmaceutical Bulk Drugs and Medicine Pharmaceutical Pellets and Granules Pharmaceutical Manufacturing Unit Indian Pharma Industry: An Investment Opportunity Manufacturing Business Ideas in Pharmaceutical Industry Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. List of APIs Products Identified 1) Amoxicillin 2) Azithromycin 3) Erythromycin Stearate/Estolate 4) Ceftriaxone 5) Cefoperazone 6) Cefixime 7) Cephalexin 8) Piperacillin Tazobactam 9) Sulbactam 10) Dexamethasone 11) Prednisolone 12) Metformin 13) Gabapentin 14) Rifampicin 15) Vitamin B1 16) Vitamin B6 17) Clindamycin phosphate 18) Clindamycin HCL 19) Streptomycin 20) Neomycin 21) Gentamycin 22) Doxycycline 23) Potassium clavulanate 24) Oxytetracycline 25) Tetracycline 26) Clarithromycin 27) Betamethasone 28) Ciprofloxacin 29) Losartan 30) Telmisartan 31) Artesunate 32) Norfloxacin 33) Ofloxacin 34) Metronidazole 35) Sulfadiazine 36) Levofloxacin 37) Meropenem 38) Paracetamol 39) Tinidazole 40) Ornidazole 41) Ritonavir 42) Diclofenac Sodium 43) Aspirin 44) Levetiracetam 45) Carbidopa 46) Levodopa 47) Carbamazepine 48) Oxcarbazepine 49) Valsartan 50) Olmesartan 51) Atorvastatin 52) Acyclovir 53) Lopinavir Market in India The Indian pharmaceutical industry is ranked third in the world in terms of production volume and 13th in terms of domestic consumption value. The Indian pharmaceutical industry size is estimated at US$25 billion in 2015. Formulations account for 65% and bulk drugs for the balance 35% in value terms. The industry is expected to reach US$55 billion by 2020. Bulk drug exports are expected to grow the fastest at 14-16% CAGR due to the growing demand of generic products and rising cost pressures that innovators face. Formulation exports are also expected to grow at 14-16% CAGR. API manufacturers in India are making efforts to strengthen their marketing capacity in the regulated markets by improving production yields, modifying production processes, and increasing sales in the international markets. More than 30% of the APIs manufactured in India are exported to countries such as US, UK, Japan, etc. The total production market of API in India was valued at approximately US$ 11 Billion in FY 2016. This market is forecasted to grow at a CAGR of around 9% during the period of FY 2016–FY 2022. Of the total domestic consumption, approximately 32% was imported. Of the total imports, China alone accounts for 57-60% of the APIs imported by India. The remaining imports are from countries such as Italy, Germany, Malaysia, and others. These facts indicate that there is plentiful scope for the domestic API market to grow, if the manufacturers are able to produce the required amount of APIs on their own, rather than importing it from other countries. Indian API Domestic Consumption The Indian API domestic consumption market will grow at a CAGR of around 10% from FY 2016 to FY 2022. Furthermore, the government is also taking various initiatives, such as allocating lands in various states for the development of API Mega Parks, increased investment in R&D, etc. to boost the industry. These initiatives will further propel the growth of the Indian API industry, as well as the domestic market for the APIs. Related Videos: - https://bit.ly/2XVNXsY Key players, such as Sun Pharma, Dr. Reddy’s, Cipla, Aurobindo Pharma, Lupin, etc., are being lured to increase their investment in the Indian API industry by providing them various lucrative offers. Tags:- #API #startupindia #APIBusiness #ActivePharmaceuticalIngredient #Amoxicillin #azithromycint #ErythromycinStearate #ceftriaxone #cefoperazone #cefixime #amoxicillin #doxycycline #cephalexin #ciprofloxacin #clindamycin #metronidazole #azithromycine #Piperacillin #tazobactam #sulbactam #dexamethasone #prednisolone #Metformin #Gabapentin #clindamycin #Clindamycin #Streptomycin #Neomycin #Gentamycin #Doxycycline #Potassiumclavulanate #Oxytetracycline #Tetracycline #Clarithromycin #Betamethasone #Ciprofloxacin #Losartan #Telmisartan #Artesunate #Norfloxacin #Ofloxacin #Metronidazole #Sulfadiazine #Levofloxacin #Meropenem #Paracetamol #Tinidazole #Ornidazole #Ritonavir #Diclofenac Sodium #Aspirin #Levetiracetam #Carbidopa #Levodopa #Carbamazepine #Oxcarbazepine #Valsartan #Olmesartan #Atorvastatin #Acyclovir #Lopinavir #businessopportunity #projectreport #DetailedProjectReport #businessconsultant #businessfeasibilityreport #BusinessPlan #startyourbusiness #investmentopportunity #growyourbusiness #startups #business #covidbusiness #covid19 #covidsmallbusiness
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Information
  • One Lac / Lakh / Lakhs is equivalent to one hundred thousand (100,000)
  • One Crore is equivalent to ten million (10,000,000)
  • T.C.I is Total Capital Investment
  • We can modify the project capacity and project cost as per your requirement.
  • We can also prepare project report on any subject as per your requirement.
  • Caution: The project's cost, capacity and return are subject to change without any notice. Future projects may have different values of project cost, capacity or return.

Add multiple items to inquiry
Select the items and then press Add to inquiry button

Page 20 of 26 | Total 259 projects in this category
« Previous   Page 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 .... 20 25 26   Next »

About NIIR PROJECT CONSULTANCY SERVICES

Hide »

NIIR PROJECT CONSULTANCY SERVICES (NPCS) is a reliable name in the industrial world for offering integrated technical consultancy services. NPCS is manned by engineers, planners, specialists, financial experts, economic analysts and design specialists with extensive experience in the related industries.

Our various services are: Detailed Project Report, Business Plan for Manufacturing Plant, Start-up Ideas, Business Ideas for Entrepreneurs, Start up Business Opportunities, entrepreneurship projects, Successful Business Plan, Industry Trends, Market Research, Manufacturing Process, Machinery, Raw Materials, project report, Cost and Revenue, Pre-feasibility study for Profitable Manufacturing Business, Project Identification, Project Feasibility and Market Study, Identification of Profitable Industrial Project Opportunities, Business Opportunities, Investment Opportunities for Most Profitable Business in India, Manufacturing Business Ideas, Preparation of Project Profile, Pre-Investment and Pre-Feasibility Study, Market Research Study, Preparation of Techno-Economic Feasibility Report, Identification and Selection of Plant, Process, Equipment, General Guidance, Startup Help, Technical and Commercial Counseling for setting up new industrial project and Most Profitable Small Scale Business.

NPCS also publishes varies process technology, technical, reference, self employment and startup books, directory, business and industry database, bankable detailed project report, market research report on various industries, small scale industry and profit making business. Besides being used by manufacturers, industrialists and entrepreneurs, our publications are also used by professionals including project engineers, information services bureau, consultants and project consultancy firms as one of the input in their research.

^ Top